The Institute for Clinical and Economic Review has developed a draft protocol for annual reviews of drug price increases.
Under the protocol, ICER will analyze drugs that prompt the most U.S. healthcare spending and review those posting major price hikes in the past two years. The group will then ask drugmakers to justify the price increases.
The review panel will include representatives from insurers, patient advocacy groups and drugmakers. ICER said the initial report will analyze 13 drugs.